Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

Myriad Genetics, Inc.MYGN introduced riskScore under its myRisk Hereditary Cancer testing portfolio. The launch is aimed at solidifying the company's footprint in the rapidly growing hereditary cancer testing market. Based in Salt Lake City, UT, this leading molecular diagnostics and personalized medicines provider intends to make riskScore a precision medical tool for patients who use myRisk to get their tests done.

Notably, riskScore helps determine a woman's risk of developing breast cancer by combining genetic markers throughout the genome with the patient's family and clinical history.

Per management, this highly advanced prediction tool will also aid 90% of the patients with negative results for heredity cancer genes to derive proper conclusions.

In June, the company had presented encouraging data from a 2,000-patient clinical study with myRisk Hereditary Cancer testsat the American Society of Clinical Oncology (ASCO). The results highlighted the importance of the multi-gene panel testing for advancement of the hereditary cancer-risk evaluation platform. Per management, around 50% of the identified mutations were found in patients who did not comply with the testing guidelines. The study also found 34% of identified mutations in unexpected genes.

Myriad Genetics has been riding high on strength in the Heriditary Cancer testing space. In the last reported quarter, the company saw 6% year-over-year rise in Heriditary Cancer testing volumes, marking the third consecutive quarter of sequential growth.

Per a report by DPI Research on Medium, the breast cancer screening market in the United States is expected to reach a value of roughly $5.8 billion by 2022. Moreover, per an article by BrestCancer.Org, approximately 252,710 new cases of invasive breast cancer in women are likely to be diagnosed in the United States in 2017. They also project 63,410 new cases of non-invasive (in situ) breast cancer this year as well.

We believe an ageing population, rising awareness and expenditure in healthcare will continue to drive growth in the breast cancer screening market. However, this market is dominated by many well established players, Quest Diagnostics DGX being the most prominent one. In this space, Quest Diagnostics' Quest Vantage services help in the discovery of genetic variants related to the hereditary risk of 15 types of cancer, including breast, colorectal, pancreatic and renal.

Moreover, Myriad Genetics has been gaining investor confidence on consistently positive results. Over the past three months, the company's share price has outperformed the broader industry . The stock has gained 41%, higher than the broader industry's 12.6%. The company has also outperformed the 0.7% gain of the S&P 500 market over the same time frame.

Zacks Rank & Key Picks

Myriad Genetics carries a Zacks Rank #3 (Hold). A couple of better-ranked medical stocks are Edwards Lifesciences Corporation EW and Lantheus Holdings, Inc. LNTH . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 23.6% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 30.2% over the last six months.

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without . More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.

S ee Stocks Now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More